Literature DB >> 21383200

Inflammation-dependent secretion and splicing of IL-32{gamma} in rheumatoid arthritis.

Bas Heinhuis1, Marije I Koenders, Fons A van de Loo, Mihai G Netea, Wim B van den Berg, Leo A B Joosten.   

Abstract

Different splice variants of the proinflammatory cytokine IL-32 are found in various tissues; their putative differences in biological function remain unknown. In the present study, we report that IL-32γ is the most active isoform of the cytokine. Splicing to one less active IL-32β appears to be a salvage mechanism to reduce inflammation. Adenoviral overexpression of IL-32γ (AdIL-32γ) resulted in exclusion of the IL-32γ-specific exon in vitro as well as in vivo, primarily leading to expression of IL-32β mRNA and protein. Splicing of the IL-32γ-specific exon was prevented by single-nucleotide mutation, which blocked recognition of the splice site by the spliceosome. Overexpression of splice-resistant IL-32γ in THP1 cells or rheumatoid arthritis (RA) synovial fibroblasts resulted in a greater induction of proinflammatory cytokines such as IL-1β, compared with IL-32β. Intraarticular introduction of IL-32γ in mice resulted in joint inflammation and induction of several mediators associated with joint destruction. In RA synovial fibroblasts, overexpression of primarily IL-32β showed minimal secretion and reduced cytokine production. In contrast, overexpression of splice-resistant IL-32γ in RA synovial fibroblasts exhibited marked secretion of IL-32γ. In RA, we observed increased IL-32γ expression compared with osteoarthritis synovial tissue. Furthermore, expression of TNFα and IL-6 correlated significantly with IL-32γ expression in RA, whereas this was not observed for IL-32β. These data reveal that naturally occurring IL-32γ can be spliced into IL-32β, which is a less potent proinflammatory mediator. Splicing of IL-32γ into IL-32β is a safety switch in controlling the effects of IL-32γ and thereby reduces chronic inflammation.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21383200      PMCID: PMC3064318          DOI: 10.1073/pnas.1016005108

Source DB:  PubMed          Journal:  Proc Natl Acad Sci U S A        ISSN: 0027-8424            Impact factor:   11.205


  28 in total

1.  Improved prediction of signal peptides: SignalP 3.0.

Authors:  Jannick Dyrløv Bendtsen; Henrik Nielsen; Gunnar von Heijne; Søren Brunak
Journal:  J Mol Biol       Date:  2004-07-16       Impact factor: 5.469

2.  Identification of a novel gene expressed in activated natural killer cells and T cells.

Authors:  C A Dahl; R P Schall; H L He; J S Cairns
Journal:  J Immunol       Date:  1992-01-15       Impact factor: 5.422

3.  Involvement of IL-32 in activation-induced cell death in T cells.

Authors:  Chiho Goda; Taisuke Kanaji; Sachiko Kanaji; Go Tanaka; Kazuhiko Arima; Shigeaki Ohno; Kenji Izuhara
Journal:  Int Immunol       Date:  2006-01-12       Impact factor: 4.823

4.  Exon truncation by alternative splicing of murine ICAM-1.

Authors:  Joseph P Mizgerd; Matt R Spieker; Michal M Lupa
Journal:  Physiol Genomics       Date:  2002-12-26       Impact factor: 3.107

5.  Exclusion of an exon in monocyte alpha-1-antitrypsin mRNA after stimulation of U937 cells by interleukin-6.

Authors:  N Kalsheker; T Swanson
Journal:  Biochem Biophys Res Commun       Date:  1990-11-15       Impact factor: 3.575

6.  Interleukin-32: a cytokine and inducer of TNFalpha.

Authors:  Soo-Hyun Kim; Sun-Young Han; Tania Azam; Do-Young Yoon; Charles A Dinarello
Journal:  Immunity       Date:  2005-01       Impact factor: 31.745

7.  IL-32 synergizes with nucleotide oligomerization domain (NOD) 1 and NOD2 ligands for IL-1beta and IL-6 production through a caspase 1-dependent mechanism.

Authors:  Mihai G Netea; Tania Azam; Gerben Ferwerda; Stephen E Girardin; Mark Walsh; Jong-Sung Park; Edward Abraham; Jin-Man Kim; Do-Young Yoon; Charles A Dinarello; Soo-Hyun Kim
Journal:  Proc Natl Acad Sci U S A       Date:  2005-10-31       Impact factor: 11.205

8.  Control of adenovirus E1B mRNA synthesis by a shift in the activities of RNA splice sites.

Authors:  C Montell; E F Fisher; M H Caruthers; A J Berk
Journal:  Mol Cell Biol       Date:  1984-05       Impact factor: 4.272

9.  IL-32, a proinflammatory cytokine in rheumatoid arthritis.

Authors:  Leo A B Joosten; Mihai G Netea; Soo-Hyun Kim; Do-Young Yoon; Birgitte Oppers-Walgreen; Timothy R D Radstake; Pilar Barrera; Fons A J van de Loo; Charles A Dinarello; Wim B van den Berg
Journal:  Proc Natl Acad Sci U S A       Date:  2006-02-21       Impact factor: 11.205

10.  Interleukin-32, CCL2, PF4F1 and GFD10 are the only cytokine/chemokine genes differentially expressed by in vitro cultured rheumatoid and osteoarthritis fibroblast-like synoviocytes.

Authors:  Nicolas Cagnard; Franck Letourneur; Abdellatif Essabbani; Valérie Devauchelle; Sylvie Mistou; Audrey Rapinat; Charles Decraene; Catherine Fournier; Gilles Chiocchia
Journal:  Eur Cytokine Netw       Date:  2005-12       Impact factor: 2.737

View more
  48 in total

1.  Neuroinflammatory and Amyloidogenic Activities of IL-32β in Alzheimer's Disease.

Authors:  Hyung-Mun Yun; Jin A Kim; Chul Ju Hwang; Peng Jin; Myung Ki Baek; Jin Moo Lee; Ji Eun Hong; Sang Min Lee; Sang Bae Han; Ki Wan Oh; Dong Young Choi; Do Young Yoon; Jin Tae Hong
Journal:  Mol Neurobiol       Date:  2014-08-27       Impact factor: 5.590

2.  IL-32, a potential therapeutic target for rheumatoid arthritis?

Authors:  Qiang Xie; Cheng Huang; Jian Zhong; Wen-Wen Shen; Shi-Cun Wang; Jun Li
Journal:  Rheumatol Int       Date:  2013-05-23       Impact factor: 2.631

3.  Interleukin-32β stimulates migration of MDA-MB-231 and MCF-7cells via the VEGF-STAT3 signaling pathway.

Authors:  Jeong Su Park; Su Yun Choi; Jeong-Hyung Lee; Maria Lee; Eun Sook Nam; Ae Lee Jeong; Sunyi Lee; Sora Han; Myeong-Sok Lee; Jong-Seok Lim; Do Young Yoon; Yongil Kwon; Young Yang
Journal:  Cell Oncol (Dordr)       Date:  2013-10-10       Impact factor: 6.730

4.  IL-32 induces indoleamine 2,3-dioxygenase+CD1c+ dendritic cells and indoleamine 2,3-dioxygenase+CD163+ macrophages: Relevance to mycosis fungoides progression.

Authors:  Hanako Ohmatsu; Daniel Humme; Juana Gonzalez; Nicholas Gulati; Markus Möbs; Wolfram Sterry; James G Krueger
Journal:  Oncoimmunology       Date:  2016-05-05       Impact factor: 8.110

5.  Human IL-32 expression protects mice against a hypervirulent strain of Mycobacterium tuberculosis.

Authors:  Xiyuan Bai; Shaobin Shang; Marcela Henao-Tamayo; Randall J Basaraba; Alida R Ovrutsky; Jennifer L Matsuda; Katsuyuki Takeda; Mallory M Chan; Azzeddine Dakhama; William H Kinney; Jessica Trostel; An Bai; Jennifer R Honda; Rosane Achcar; John Hartney; Leo A B Joosten; Soo-Hyun Kim; Ian Orme; Charles A Dinarello; Diane J Ordway; Edward D Chan
Journal:  Proc Natl Acad Sci U S A       Date:  2015-03-27       Impact factor: 11.205

6.  IL-32 promotes angiogenesis.

Authors:  Claudia A Nold-Petry; Ina Rudloff; Yvonne Baumer; Menotti Ruvo; Daniela Marasco; Paolo Botti; Laszlo Farkas; Steven X Cho; Jarod A Zepp; Tania Azam; Hannah Dinkel; Brent E Palmer; William A Boisvert; Carlyne D Cool; Laima Taraseviciene-Stewart; Bas Heinhuis; Leo A B Joosten; Charles A Dinarello; Norbert F Voelkel; Marcel F Nold
Journal:  J Immunol       Date:  2013-12-11       Impact factor: 5.422

7.  Interplay between thyroid cancer cells and macrophages: effects on IL-32 mediated cell death and thyroid cancer cell migration.

Authors:  Yvette J E Sloot; Katrin Rabold; Thomas Ulas; Dennis M De Graaf; Bas Heinhuis; Kristian Händler; Joachim L Schultze; Mihai G Netea; Johannes W A Smit; Leo A B Joosten; Romana T Netea-Maier
Journal:  Cell Oncol (Dordr)       Date:  2019-06-14       Impact factor: 6.730

8.  Interleukin 32 (IL-32) contains a typical α-helix bundle structure that resembles focal adhesion targeting region of focal adhesion kinase-1.

Authors:  Bas Heinhuis; Marije I Koenders; Wim B van den Berg; Mihai G Netea; Charles A Dinarello; Leo A B Joosten
Journal:  J Biol Chem       Date:  2011-12-27       Impact factor: 5.157

9.  Interleukin-32 isoforms: expression, interaction with interferon-regulated genes and clinical significance in chronically HIV-1-infected patients.

Authors:  Katia Monteleone; Pierluigi Di Maio; Giulia Cacciotti; Francesca Falasca; Maurizio Fraulo; Mario Falciano; Ivano Mezzaroma; Gabriella D'Ettorre; Ombretta Turriziani; Carolina Scagnolari
Journal:  Med Microbiol Immunol       Date:  2014-02-20       Impact factor: 3.402

Review 10.  New insights into the epigenetics of inflammatory rheumatic diseases.

Authors:  Esteban Ballestar; Tianlu Li
Journal:  Nat Rev Rheumatol       Date:  2017-09-14       Impact factor: 20.543

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.